Localizing radioimmunotherapy via nanochannel device for sustained intratumoral drug delivery for solid tumor treatment.

37Background: Immune related adverse events still occur in up to 91% of patients receiving immunotherapy. Intratumoral administration is a potential solution to limit these events by reducing syste...